10th National - Strategy Summit on Paragraph IV Litigation

Memo

Successful IP Litigation Strategies for Brand and Generic Pharmaceutical Manufacturers Carve-outs, estoppel, restrictions on venue, and ANDA litigation remain some of the hottest contested issues under Paragraph IV of the Hatch-Waxman Act. Via Momentum's fully interactive platform, join us as our conference faculty of esteemed judges, leading in-house counsel and experienced practitioners provide you with the tactics, tools, strategies and insight you need when litigating Paragraph IV cases. Top Reasons to Attend1. Obtain the thoughts of Federal Circuit and PTAB Judges regarding to best practices when arguing a case related to pharmaceutical IP2. Put the outcomes of "GSK v. Teva" and "Minerva Surgical v Hologic Inc" into use as you prepare for upcoming Paragraph IV litigation3. Strengthen your abilities to protect company intellectual property overseas by examining current international regulations and court rulings4. Further understand how President Biden's potential waiver in the fight against COVID-19 may affect the IP rights of pharmaceuticals and biologics going forward 5. Network with leading Paragraph IV experts to ready yourself for future litigation   Tickets:  https://go.evvnt.com/810141-1?pid=5569  Date and Time: On Monday September 13, 2021 at 8:00 am (ends Tuesday September 14, 2021 at 5:00 pm) Price:General Admission: USD 895.00